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Summary MIBl proliferation rate (MIBl-PR) and total S-phase fraction (SPF) were retrospectively determined in formalin-fixed, paraffin-
embedded sections of 90 primary node-negative breast carcinomas. None of the patients had received adjuvant systemic therapy. Median
follow-up in patients still alive atthe time of analysis was 37.5 months (16-72 months). lmmuno6taining of Ki-67 antigen was performed using
the monoclonal antibody MIBl and the APAAP technique. An adjacent 50-gm paraffin section was used for flow cytometric S-phase
determination. Results were compared to established clinicopathological prognostic factors. MIBl-PR was significantly correlated to grading
(P = 0.018); SPF was significantly correlated with tumour size (P = 0.041) and inversely with steroid hormone receptor status (P = 0.03). A
significant correlation between MIBl-PR and SPF was found in aneuploid (P = 0.025) but not in diploid tumours (P = 0.164). In univariate
analysis, both MIBl -PR (optimized cut-off of 25%) and SPF (optimized cut-off of 8%) were significant prognostic factors for disease-free
survival (DFS) (MIBl-PR, P= 0.0224; SPF, P= 0.0028). In multivariate analysis, however, only SPF remained significant; it was the strongest
prognostic factor for DFS (P = 0.0073), stronger than MIBl-PR or established clinicopathological prognostic factors. We thus conclude that
MIBl-PR and SPF provide additional prognostic information in node-negative breast cancer. However, in our study, flow cytometrically
determined SPF had the greater prognostic impact.
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In breast cancer, node-negative patients constitute a subgroup at
decreased risk of relapse. However, even within this 'low-risk'
population, only about 70% turn out to have been cured by surgery
alone. Up to 30% ofall node-negative patients will relapse within
10 years after primary therapy and eventually die from the disease
(Fisher et al, 1969). Numerous additional histopathological and
clinical prognostic factors, such as tumour size, tumourgrade, age,
steroid hormone receptor status or menopausal status, have been
established as being of clinical value to help identify those node-
negative patients who would profit from therapy. In order to refine
this identification further, new prognostic markers are needed to
identify high-risk patients even within 'classical' risk groups, thus
enabling a more individualized approach to adjuvant systemic
therapy.
Markers for tumour proliferation and growth rate have been
suggested as new prognostic parameters in breast cancer for a
number of years. However, their prognostic impact is still contro-
versial, partly because of non-standardized determination
methods. The Ki-67 antigen was first described by Gerdes et al
(1983). During the cell cycle, Ki-67 immunohistochemical
staining can be seen in varying intensity duringG, and S-phase, as
well as in G2/M. The strongest Ki-67 staining is found during
G2/M phase (Gerdes et al, 1984). MIB1 is a murine monoclonal
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antibody prepared against epitopes of recombinant Ki-67 antigen
(Cattoretti et al, 1992). In contrast to conventional Ki-67 anti-
bodies, MIB1 can recognize the antigen in formalin-fixed,
paraffin-embedded tissue sections (Cuevas et al, 1993). Recent
studies suggest that conventional Ki-67 antibodies and MIB1 may
detect different epitopes of the Ki-67 antigen (Weidner et al,
1994). The use of paraffin-embedded tissue specimens for flow
cytometric DNA analysis was first suggested by Hedley et al
(1983). However, because ofthe lack at that time ofproper evalu-
ation software, more sophisticated S-phase determination has only
been possible on paraffin material for the last few years (Weaver
et al, 1990). Numerous reports have been published within the last
few years about the role of the proliferation-associated Ki-67
antigen and/or S-phase fraction in breast cancer. For instance,
Lelle et al (1986) described a significant difference in the size
of growth fractions - as detected by Ki-67 immunostaining -
between benign and malignant breast lesions. Other authors indi-
cated that breast cancer patients with highly proliferating tumours
as assessed by Ki-67 immunostaining (Sahin et al, 1991; Veronese
et al, 1993) or S-phase evaluation (Clark et al, 1989; Sigurdsson et
al, 1990) have an increased risk ofrecurrence.
In this study, we evaluated the prognostic impact of MIB1-PR
and total S-phase fraction (SPF) in comparison with established
prognostic factors solely in node-negative breast cancer patients
who did not receive any adjuvant systemic therapy after primary
surgery. Both markers were determined on adjacent sections ofthe
same formalin-fixed, paraffin-embedded tissue sample to ensure
optimal data comparability. We present the results of 90 node-
negative breast carcinomas over a median follow-up time of
37.5 months.
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MATERIAL AND METHODS
Patients and tissue specimens
Formalin-fixed, paraffin-embedded tissue specimens from 90
consecutively collected primary node-negative breast carcinomas
(1987-91) were evaluated. Only tissue sections with a content of
more than 80% tumour tissue were selected from the archives of
the Department of Pathology (Technische Universitat Munchen).
The following data were available for each patient: age,
menopausal status, tumour size, tumourgrade (Bloom-Richardson
score), histological type of tumour (WHO classification),
biochemical oestrogen and progesterone receptor status [assessed
by dextran-coated charcoal technique (DCC); cut-off point
10 fmol mg-' protein], lymph vessel invasion and tumour necrosis
(studied on haematoxylin-eosin-stained slides). Tumour necrosis
is defined as an area of tumour tissue destruction, not as mere
single-cell necrosis. (It expresses a possible consequence of an
imbalance between tumour proliferation and efficient tumour
angiogenesis.) Follow-up examinations were performed at regular
intervals. None of the patients received any adjuvant systemic
therapy after primary therapy, which consisted of either breast-
conserving surgery or mastectomy as well as axillary lymph node
dissection. Radiation ofthe remaining breast tissue was performed
in all cases ofbreast-conserving surgery.
Immunostaining of Ki-67 antigen
Immunostaining was performed on 4-jim-thick, formalin-fixed,
paraffin-embedded tissue sections using the alkaline phos-
phatase-anti-alkaline phosphatase (APAAP) method (see Figure
1). The MIB1 antibody and the APAAP dual system were kindly
provided by Dianova GmbH (Hamburg, Germany). Details of the
staining method have been previously described (Cordell et al,
1984). In brief, sections were attached on aminosilane-treated
slides and dried overnight at 37°C. After rehydration and two
washes in phosphate-buffered saline (PBS), the sections were
immersed in a glass container containing 10 mmol 1-' sodium
citrate buffer (pH 6.0) and processed in a microwave oven three
times for 5 min at 750 W. The sections were then rinsed in PBS,
followed by incubation (4°C, overnight) with the mouse mono-
clonal antibody MIB1 (200 jg of IgG ml-') at a 1:20 dilution in
PBS supplemented with 1% bovine serum albumin (BSA).
Following gentle rinsing, the sections were incubated with the
rabbit anti-mouse antibody (1 mg ofIgG per ml) at a 1:50 dilution
in PBS containing 20% normal human serum (30 min, room
temperature). The sections were washed again and then incubated
with the APAAP complex (1:50 in PBS, 30 min, room tempera-
ture). Texas fast red (Sigma, Munich, Germany) was used as alka-
line phosphatase substrate chromogen. The sections were briefly
counterstained with haematoxylin and coverslipped. Lymph node
tissue was used as apositivecontrol; as a negative control, staining
was performed without primary antibody.
Staining assessment
Assessment of stained tumour cell nuclei was performed semi-
quantitatively by two independent investigators (PD, WN). All
nuclei with detectable staining above the background level were
scored as positive. Both pathologists counted at least 500 tumour
cell nuclei that had been randomly chosen in at least flve different
view fields. Depending on histological tumour type and tumour
cell distribution, the percentage of reactive nuclei was counted at
100- to 400-fold magnification.
Tissue preparation for flow cytometry
One 50-jm formalin-fixed, paraffin-embedded tissue section per
patient was processed according to our own modified Hedley tech-
nique (Harbeck et al, 1991). After dewaxing in two changes of
Rotihistol, a xylene substitute (Roth, Karlsruhe, Germany), and
rehydration in an ethanol sequence of decreasing concentration,
enzymatic digestion was performed in 2 ml of 0.5% pepsin (in
isotonic sodium chloride, pH 1.5, 37°C, 2 h) (Sigma, Munich,
Germany). The resulting nuclei were washed in cold PBS, filtered
through a 75-jm nylon mesh and resuspended in PBS containing
5 mM EDTA (Merck, Mannheim, Germany) and 100 units RNAase
A (Sigma). After a 15-min incubation period at room temperature,
the nuclei were stained for flow cytometry with propidium iodide
(PI) (Sigma) and left on ice in a dark chamber for at least 5 min.
Fluorescence was stable for up to 2 h. Propidium iodide fluores-
cence of the stained nuclei was recorded on a FACScan (Becton
Dickinson, Heidelberg, Germany) flow cytometer using the
Consort 30 program (see Figure 2). Foreach sample at least 20 000
events were recorded. Peripheral human blood lymphocytes (PBL)
isolated by Ficoll density gradient centrifugation (Boyum, 1968)
Table 1 MIBl-PR, total S-phase fraction and ploidy in node-negative breast
cancer: patient characteristics (n = 90)
Age (median in years)
Tumour size (median in cm)
<2.0 cm
> 2.0 and < 5.0 cm
> 5.0 cm
Hormone receptor status
Positive
Negative
Menopausal status
Premenopausal
Post-menopausal
Grading
Gl
G2
G3
Histological type
Invasive ductal
Invasive lobular
Medullary carcinoma
Mucinous carcinoma
MIBl proliferation rate (MIBl-PR)
Low (< 25%)
High (> 25%)
Total S-phase fraction (SPF)
Low (< 8%)
High (> 8%)
Ploidy
Diploid
Near diploid
Aneuploid
Multiploid
Tetraploid
55.7 (range 36.3-81.7)
2.2 (range 0.5-7.1)
41 (45.6%)
46 (51.1%)
3 (3.3%)
69 (76.7%)
21 (23.3%)
57 (63.3%)
33 (36.7%)
5 (5.6%)
61 (67.8%)
24 (26.6%)
75 (83.3%)
9 (10%)
5 (5.6%)
1 (1.1%)
75 (83%)
15 (17%)
61 (68%)
29 (32%)
43 (48%)
2 (2%)
36 (40%)
2 (2%)
7 (8%)
British Journal ofCancer (1997) 75(10), 1525-1533 0 CancerResearch Campaign 1997MIB1 (Ki-67) and S-phase in node-negative breastcancer 1527
B
.;. ,,,,M
..1
Figure 1 Immunohistochemical detection of Ki-67 antigen in node-negative breast cancer using the MIBl antibody. Tumour cell nuclei stained in red show
immunoreactivity for Ki-67 antigen, thus indicating proliferation (APAAP immunostaining, original magnification x 200). (A) 10% MIBl-positive tumour cells in an
invasive ductal carcinoma with partly intraductal component. (B) 30% MlBl-positive tumour cells in an invasive ductal carcinoma. (C) 60% MlBl-positive tumour
cells in an invasive ductal carcinoma. (D) 80% MlBl-positive tumour cells in an invasive lobular carcinoma
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Figure 2 Flow cytometric DNA analysis in node-negative breast cancer. Diploid tumour (left) and aneuploid tumour (right). Top, forward light scatter (FSC)/side
light scatter (SSC); middle, forward light scatter (FSC)/propidium iodide (PI) fluorescence; bottom, propidium iodide fluorescence histogram
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Table 2 MIBl-PR, total S-phase fraction (SPF) and ploidy in node-negative
breast cancer and their correlation to other prognostic factors
Prognostic MIB1-PR SPF Ploidy
factors (< vs > 25%) (< vs > 8%) (diploid vs aneuploid)
Tumour size (cm) NS* P= 0.041 NS*
Hormone receptor NS* P = 0.030 P = 0.05
status (negative vs positive)
Menopausal status NS* NS* P = 0.05
(pre vs post)
Grading P = 0.018 NS* NS*
Lymph vessel NS* NS* NS*
invasion
(not present vs present)
Tumor necrosis NS* NS* NS*
(not present vs present)
*Correlation not significant (P> 0.05), Mann-Whitney U-test.
served as an external control for preparation quality. These refer-
ence cells were fixed in 10% phosphate-buffered formaldehyde
(distilled water, pH 7.0, 4°C, overnight), then digested with pepsin
and stained with propidium iodide as described for paraffin-
embedded sections.
Computer-based DNA analysis
Stored flow cytometric data were transferred to an IBM-compat-
ible computer and then analysed using the ModFit Software
package (Verity House, Maine, USA). This software is designed to
distinguish between single nuclei, debris and aggregates released
from paraffin-embedded tissue sections (Weaver et al, 1990;
Bagwell et al, 1991). Therefore, gating of cells was not applied.
Aneuploidy was assumed iftwo distinct GJG, peaks were present
(Hedley, 1989). In such cases, theGJG, peak with the lowest fluo-
rescence channel number was classified as diploid. Total S-phase
fraction was used for further analysis. Tumours with a coefficient
ofvariation (CV) over 10% were not included in this study.
Statistical methods
Optimal cut-off values for MIB1-PR and total S-phase fraction
(SPF) to discriminate between low and high levels were deter-
mined using isotonic regression and CART (classification and
regression trees) technique. The value with maximal log-rank test
was taken fordiscrimination ofhigh and low. Correlations between
MIB1-PR and SPF as well as other clinicopathological prognostic
factors were analysed using the U-test of Mann-Whitney.
Correlation coefficients were calculated according to Spearman.
Probability curves for disease-free survival (DFS) were calculated
according to Kaplan and Meier. The relative risk ofMIB1-PR, SPF
and various established prognostic factors were estimated by Cox's
proportional hazard model using the BMDP software package
(BMDP Statistical Software, Los Angeles, CA, USA) and applying
optimized cut-offpoints. All tests were performed at a significance
level ofax = 0.05.
RESULTS
Patients
Complete data on MIB1-PR, total S-phase and ploidy as well as
complete clinical and pathological data were available in 90
patients with primary node-negative breast cancer. The median
follow-up time in patients still alive at time of analysis was 37.5
months (16-72 months). The series comprised 75 (83.3%) invas-
ive ductal, nine (10%) invasive lobular, five (5.6%) medullary and
one (1.1%) mucinous carcinoma. Patient and tumour characteris-
tics are shown in Table 1. Lymph vessel invasion was present in
seven (7.8%) and not present in 83 (92.2%) ofthe tumours; tumour
necrosis was present in 19 (21.1%) and not present in 71 (78.9%)
ofthe carcinomas.
Thirteen patients (14.4%) have already relapsed, and 12 patients
(12.2%) have died from the disease.
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Figure 3 MIBl proliferation rate (MIBl-PR) and disease-free survival (DFS)
in node-negative breast cancer (n = 90). -: 75 patients, eight events;
--- -: 15 patients, five events
Figure 4 Total S-phase fraction (SPF) and disease-free survival (DFS) in
node-negative breast cancer (n = 90). -: 61 patients, four events;
--- -: 29 patients, nine events
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Table 3 Disease-free survival (DFS) in node-negative breast cancer:
multivariate analysis
Prognostic P-value P-value Relative risk
factors univariate multivariate
Total S-phase 0.0028 0.0073 5.02 (1.54-16.30)
fraction (SPF)
(< vs > 8.0%)
MIBl-PR 0.0224 - -
(< vs > 25%)
Tumour necrosis 0.1069 - -
(not present vs present)
Tumour size 0.1015 - -
(<vs > 2 cm)
Hormone 0.1542 - -
receptor status
(negative vs positive)
Grading 0.4699 - -
(G1/2 vs G3)
Menopausal status 0.6166 - -
(pre vs post)
Lymph vessel invasion 0.8961 - -
(not present vs present)
MIBI immunostaining
Seventy-six tumours (84%) showed immunoreactivity with the
MIB 1 antibody. In these tumours, the percentage of stained cells
(i.e. MIB1-PR) ranged from 1% to 81%, with a mean of 18% (see
Figure 1). The common staining pattern was either diffuse or
uniform nuclear staining. In the 14 tumours (16%) without MIB1
immunoreactivity, staining was repeated on an adjacent paraffin
section to exclude experimental errors. Using isotonic regression
analysis, an optimal cut-off point of 25% was determined to
discriminate between tumours with a low or high MIB1-PR: 75
(83%) tumours showed low (< 25%) and 15 (17%) high (> 25%)
MIB1-PR (see Table 1).
Flow cytometric determination of S-phase fraction
and ploidy
Ninety node-negative tumours were analysed by flow cytometry
for ploidy status and total S-phase fraction (SPF). The median
coefficient of variation (CV) for the diploidGO/GI peak was 5.5%
(3.2-10.3%). Forty-three of the 90 patients (48%) had diploid,
two near-diploid, 36 (40%) aneuploid, two multiploid and seven
tetraploid tumours (see Table 2). For further analysis, diploid and
near-diploid tumours were grouped together as diploid tumours,
aneuploid, multiploid and tetraploid tumours as aneuploid
tumours. Total S-phase values followed a skewed distribution and
ranged from 1.08% to 26.84%, with a median of 2.61% and a
mean of 7.62%. Diploid tumours (1.08-21.93%, median 3.49%,
mean 4.59%) had a significantly lower SPF (P = 0.01) than aneu-
ploid tumours (1.63-26.84%, median 15.18%, mean 10.65%).
However, ploidy by itselfhad no prognostic impact. Cut-offdeter-
mination for SPF was therefore performed in all 90 tumours
without further subgrouping according to ploidy status. Using
isotonic regression analysis, an optimal cut-off of 8% was deter-
mined to discriminate between tumours with low or high SPF: 61
(68%) tumours had low (< 8%) and 29 (32%) high (> 8%) SPF
(see Table 2).
Correlation of MIBl to S-phase or ploidy
Only in aneuploid tumours was a significant correlation (P =
0.025) between MIB1-PR and S-phase found. In diploid tumours
the correlation was of no statistical significance (P = 0.164).
Correlation of MIB1-PR, total S-phase fraction and
ploidy to other prognostic factors
MIB1-PR was significantly correlated to tumourgrade (P = 0.018)
as well as medullary histological tumour type (P < 0.05): Low-
grade tumours (G1/2) had significantly lower percentages of
MIB1- positive cells than high-grade tumours (G3). In medullary
carcinomas, MIB1-PR was significantly higher than in other
carcinoma types. No significant correlation of MIB1-PR was
found to age, menopausal status, tumour size, presence of tumour
necrosis or lymph vessel invasion, or to oestrogen or progesterone
receptor status.
There was a significant, direct correlation oftotal S-phase frac-
tion (SPF) to tumour size (P = 0.041) as well as an inverse correla-
tion to steroid hormone receptor status (P = 0.030): in tumours
with high SPF (> 8%), lower levels ofboth oestrogen and proges-
terone receptors were found. Other established prognostic factors
were not significantly correlated to SPF.
Correlations of only borderline significance (P = 0.05) were
found between ploidy status and hormone receptor status as well
as menopausal status: 39 (87%) of all 45 diploid tumours were
steroid hormone receptor positive compared with 30 of 45 (67%)
aneuploid tumours. Among post-menopausal patients, more aneu-
ploid (59%) than diploid (41%) tumours were found compared
with the premenopausal patient group with 44% aneuploid and
56% diploid tumours (see Table 2).
Correlation of MIB1-PR, total S-phase fraction and
ploidy to survival
Ploidy was not a significant parameter in the prediction ofdisease-
free survival (DFS). Neither when grouped together into diploid vs
aneuploid tumours (P > 0.05) nor when ploidy subgroups were
considered separately (P> 0.05) did ploidy status have a significant
impact on DFS. However, both MIB1-PR (P = 0.0224) and total
S-phase fraction (P = 0.0028) were significant prognostic factors
for disease-free survival in univariate analysis (see Table 3). All
other established prognostic factors (steroid hormone receptor
status, grading, menopausal status, lymph vessel invasion, tumour
necrosis, tumour size) did not reach statistical significance in the
univariate setting. Five of the 15 patients (33%) with high MIB1-
PR (> 25%) have already relapsed compared with only 8 of 75
(11%) patients with low MIB1-PR (< 25%) (see Figure 3). Up until
now, 9 of29 patients (31%) with high SPF in their tumours (> 8%)
have relapsed compared with 4 of61 (6.6%) with low SPF (< 8%)
(see Figure 4). In multivariate analysis, total S-phase fraction was
the only significant prognostic factor for DFS (P = 0.0073) with a
relative risk of 5.02 (1.55-16.3) (see Table 3). Neither MIB1-PR
nor established prognostic factors added significant information to
DFS in the multivariate setting.
DISCUSSION
Immunohistochemical Ki-67 (MIB1) staining and flow cytometric
S-phase analysis detect different cell cycle compartments in prolif-
erating cells (Gerdes et al, 1984): the nuclear Ki-67 antigen can be
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found during G,, S- as well as G2/M phase in varying intensity. In
contrast, the flow cytometrically determined S-phase fraction only
consists of cells that are actively synthesizing DNA, thus
comprising only a small portion ofthe cell cycle. These differences
may serve as an explanation for the lack of correlation between
MIB I proliferation rate (MIB1-PR) and total S-phase fraction
(SPF) in our series of 90 node-negative breast carcinomas: only in
aneuploid tumours did we observe a direct correlation between
MIB1-PR and SPF. This is in agreement with other researchers
whose patient samples include both node-negative and node-
positive breast cancerpatients (Isola et al, 1990; Vielh et al, 1990).
Sahin et al (1991) suggested that this finding might be attributed to
the fact that in tumours with low S-phase, MIB 1 staining ofG, cells
is ofhigher impact, as it then constitutes a considerable percentage
of the cycling cells. In addition, flow cytometric DNA analysis
tends to underestimate SPF in diploid tumours. Inparaffin material,
the G(JG, peak with the lowest fluorescence channel number is
commonly considered diploid and, accordingly, all other G0/G,
peaks aneuploid, as there are no adequate external diploid controls
(Hedley et al, 1985). Tumour-infiltrating inflammatory cells as well
as benign stromal cells therefore contribute to the diploid popula-
tion and may influence S-phase analysis. Nevertheless, it has been
shown that DNA analysis in paraffin material yields results quite
similar to those in fresh tumour tissue (Kallioniemi etal, 1988). We
attempted to minimize the difficulties involved in using paraffin
material by demanding a content of at least 80% tumour tissue per
paraffin section (pathologist's report). Moreover, to optimize data
comparability, adjacent paraffin sections were used for MIB I
immunostaining and S-phase analysis. Determination methods for
both factors are simple and fast. They may be applied in a routine
laboratory ifquality control is exercised, and adequate cut-offeval-
uation is performed before results are transferred to everyday
patient management (Harbeck et al, 1994).
A remarkable observation was the absence of MIB1 immuno-
staining in some of the tumour samples although they contained a
representative tumour section. This observation is consistent with
negative results obtained in proliferation studies in breast cancer
(Sahin et al, 1991) and in different tumour types by other investi-
gators (Gorczyca et al, 1995; Graham et al, 1995). This finding
may be due to either a very low-level expression of the Ki-67
antigen, which is below the detection level for the antibody used,
or expression of a mutated form of the protein. Development of a
future generation of anti-Ki-67 antibodies may help to resolve this
question. Another possible explanation, which was based on data
obtained in cell culture, has been put forward by Verheijen et al
(1989), who suggested that protein expression may be altered in
nutritionally deprived cells.
Two different ways of assessing MIB1 positivity in a tumour
section are commonly used in the literature, i.e. counting of
random tumour cells or 'hotspot counting'. As part of our internal
testing procedure for this study, we originally performed both
methods and found that the results were substantially equivalent.
For this study, random tumour cell counting was used.
In our study, MIB1-PR was correlated to histological tumour
grade, but not to any other of the established prognostic markers.
This finding may also explain the observed correlation between
high MIB1-PR and medullary histological tumour type, a high-
grade carcinoma by definition. Other authors have also observed a
significant correlation between Ki-67 and tumour grade in breast
cancer (Lelle et al, 1986; Isola et al, 1990; Gasparini et al, 1994).
The Bloom-Richardson grading system (Bloom and Richardson,
1957), which is widely used in routine pathology, only gives a
rough estimate of the percentage of mitotic cells. A more precise
estimate of the rate of mitosis is achieved either by the mitotic
figure index, MFI (i.e. mitotic count per 1000 tumour cells) or by
the mitotic figure count, MFC (i.e. number of mitotic figures per
high-power field). Weidner et al (1994) found that there was a
stronger correlation between MFI and Ki-67 immunostaining than
between Ki-67 and either histological grade or MFC in breast
cancer. Biesterfeld et al (1995) showed that MFC had a greater
prognostic impact than the Bloom-Richardson score in their series
of 104 ductal breast carcinomas. Data concerning correlations
between Ki-67 and other cell kinetics markers in breast cancer are
controversial: a significant correlation to argyrophilic nucleolus
organizing regions (AgNOR) has been reported (Dervan et al,
1989; Ruschoff et al, 1990); however, no significant correlation
between Ki-67 and the proliferating cell nuclear antigen (PCNA)
has been found (Gasparini et al, 1994). For Ki-67 as well as S-
phase fraction, a significant correlation with the thymidine
labelling index has been reported (McDivitt et al, 1986; Kamel et
al, 1989). In addition, McDivitt et al (1986) have also demon-
strated a significant correlation between mitotic rate and SPF.
In our series, total S-phase fraction was significantly correlated
to tumour size as well as steroid hormone receptor status. There is
no consensus in the literature on SPF and its correlation to estab-
lished prognostic factors. While a number of reports indicate an
inverse relationship between hormone receptor status and SPF
(McDivitt et al, 1986; Kallioniemi et al, 1987; Dressler et al, 1988;
Sigurdsson et al, 1990; Vielh et al, 1990), only a few reports found
a correlation between tumour size and SPF (Sigurdsson et al,
1990). Fisher et al (1969) have linked tumour size to rate ofprolif-
eration and length ofcell cycle in their study on tumour size and its
correlation to recurrence rates.
Ourrate ofaneuploidy (50%) is quite similarto that in the literature
[McDivitt et al, 1986 (55%); Kallioniemi et al, 1987 (60%); Dressler
et al, 1988 (57%); Sigurdsson et al, 1990 (58%)], even though some
authors have reported somewhat higher percentages [Hedley et al,
1987 (72%); Clark et al, 1989 (68%)]. We observed a borderline
significant correlation between ploidy and menopausal status as well
as hormone receptor status: aneuploidy was more commonly seen in
post-menopausalpatients. Among aneuploidtumours,thosethat were
steroid hormone receptor negative were significantly more frequent
than among diploid tumours. Similar findings were reported by
Hedley et al (1987) and Kallioniemi et al (1988).
In node-positive breast cancer patients, adjuvant systemic
therapy is the generally accepted therapeutic standard. However,
for the so-called 'low-risk' group of node-negative patients, treat-
ment recommmendations are still controversial. This underlines
the demand for better prognostic predictors for this group of
patients in order to individualize adjuvant therapy and thus avoid
overtreatment of patients who will be cured by surgery alone. To
evaluate the quality of the proliferation markers MIB 1-PR and
total S-phase fraction as new prognostic indicators, we therefore
concentrated on this clinically relevant subgroup of node-negative
patients. In contrast to other studies including NO and N 1 patients,
follow-up data of our patient collective was not altered by effects
ofadjuvant systemic therapy.
In the present study, ploidy had no prognostic impact for
disease-free survival (DFS). In the literature there are conflicting
reports about the importance of ploidy in breast cancer. Some
authors saw significantly worse survival in patients with aneuploid
tumours (Kallioniemi et al, 1987; Clark et al, 1989; Aubele et al,
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1995), while others felt that ploidy did not yield additional prog-
nostic information on survival (O'Reilly et al, 1990; Sigurdsson et
al, 1990). Both MIB1-PR and SPF were significant prognostic
factors for DFS in our univariate analysis. Established prognostic
factors did not have significant impact on DFS. Thus, MIB1-PR
and SPF provided additional prognostic information in our node-
negative breast cancer patients. However, when both factors were
compared with established prognostic factors in multivariate
analysis, only SPF retained its significant prognostic impact on
DFS. Neither MIB 1-PR nor tumour size, steroid hormone receptor
status, menopausal status or tumour grade were significant indica-
tors of DFS in multivariate analysis. This is in agreement with
recent data ofGasparini et al (1994) evaluating 168 primary breast
cancer patients (NO and NI) over a median follow-up of 60
months. In their study, Ki-67 and SPF were significant prognostic
factors for DFS as well as overall survival (OS) in univariate
analysis. However, in multivariate analysis Ki-67 lost its signifi-
cant impact, and only S-phase fraction and nodal status remained
significant predictors for DFS and OS. Sahin et al (1991) evalu-
ated 42 node-negative breast cancer patients over a median follow-
up of 88 months. In their study, Ki-67 immunostaining was a
significant prognostic factor in univariate analysis, whereas S-
phase only reached borderline significance. However, because of
the small patient number, they did not evaluate their factors in a
multivariate setting.
In conclusion, MIB 1-PR and total S-phase fraction had signifi-
cant prognostic impact in our series of 90 node-negative breast
cancer patients after a median follow-up of more than 3 years. Our
data suggest that total S-phase fraction is a stronger prognostic
factor than MIB 1-PR and may therefore be better suited for clin-
ical decision-making. However, data in the literature on the prog-
nostic importance of proliferation markers in primary breast
cancer are still controversial. There are only a few studies evalu-
ating more than one proliferation marker and directly comparing
them in the same set of patients. Further studies are therefore
warranted to establish whether proliferation markers are indeed
valuable prognostic indicators and which proliferation marker is
the most suitable for the clinicopathological routine. In particular,
international standardization of detection methods has to be
improved before transfer to patient management can be attempted.
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